{"id":2091,"date":"2019-10-01T20:19:00","date_gmt":"2019-10-01T18:19:00","guid":{"rendered":"https:\/\/idibell.cat\/?page_id=2091"},"modified":"2024-04-11T10:27:57","modified_gmt":"2024-04-11T08:27:57","slug":"neurofarmacologia-i-dolor","status":"publish","type":"page","link":"https:\/\/idibell.cat\/recerca\/area-de-neurociencies\/programa-de-neurociencies\/neurofarmacologia-i-dolor\/","title":{"rendered":"Neurofarmacologia i Dolor"},"content":{"rendered":"\n
El grup centra la seva recerca en la comprensi\u00f3 de la funci\u00f3 dels receptors de neurotransmissors en salut i malaltia. Per tant, el seu principal objectiu \u00e9s traduir els resultats del laboratori al pacient i la pr\u00e0ctica cl\u00ednica. En conseq\u00fc\u00e8ncia, busquen noves estrat\u00e8gies farmacol\u00f2giques per assolir una gesti\u00f3 efica\u00e7 de malalties neurol\u00f2giques, neuropsiqui\u00e0triques, inflamat\u00f2ries, autoimmunes i del dolor.<\/p>\n
Alemany A, Millat Martinez P, Corbacho Monn\u00e9 M, Malchair P, Ouchi D, Ruiz Comellas A, Ram\u00edrez Morros A, Rodr\u00edguez Codina J, Amado Simon R, Videla S, Costes G, Capdevila J\u00e1uregui M, Torrano Soler P, San Jos\u00e9 A, Bonet Papell G, Puig J, Otero A, Ruibal Suarez JC, Zarauza Pellejero A, Llopis Roca F, Rodriguez Cortez O, Garcia V, Vidal Alaball J, Millan A, Contreras E, Grifols JR, Ancochea \u00c0, Galvan Femenia I, Piccolo Ferreira F, Bonet M, Cantoni J, Prat N, Ara J, Forcada Arcarons A, Farr\u00e9 M, Pradenas E, Blanco J, \u00c0ngel Rodriguez Arias M, Fern\u00e1ndez Rivas G, Marks M, Bassat Q, Blanco I, Baro B, Clotet B, Mitj\u00e0 O, CONV ERT G. High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial<\/strong>. Lancet Respir Med. 2022;10(3):278-288. doi:10.1016\/S2213-2600(21)00545-2.<\/p>\n Millat Martinez P, Gharbharan A, Alemany A, Rokx C, Geurtsvankessel C, Papageourgiou G, van Geloven N, Jordans C, Groeneveld G, Swaneveld F, van der Schoot E, Corbacho Monn\u00e9 M, Ouchi D, Piccolo Ferreira F, Malchair P, Videla S, Garc\u00eda V, Ruiz Comellas A, Ram\u00edrez Morros A, Rodriguez Codina J, Amado Simon R, Grifols JR, Blanco J, Blanco I, Ara J, Bassat Q, Clotet B, Baro B, Troxel A, Zwaginga JJ, Mitj\u00e0 O, Rijnders B, CoV Early study G, COnV ert study G. Prospective individual patient data meta-analysis of two randomized trials on convalescent plasma for COVID-19 outpatients<\/strong>. Nat. Commun. 2022;13(1):2583-2583. doi:10.1038\/s41467-022-29911-3.<\/p>\n Parameswaran J, Goicoechea L, Planas Serra L, Pastor A, Ruiz M, Calingasan NY, Guilera C, Aso E, Boada J, Pamplona R, Portero Ot\u00edn M, de la Torre R, Ferrer I, Casasnovas C, Pujol A, Fourcade S. Activating cannabinoid receptor 2 preserves axonal health through GSK-3\u00df\/NRF2 axis in adrenoleukodystrophy<\/strong>. Acta Neuropathol. 2022;144(2):241-258. doi:10.1007\/s00401-022-02451-2.<\/p>\n Solis O, Beccari AR, Iaconis D, Talarico C, Ruiz Bedoya CA, Nwachukwu JC, Cimini A, Castelli V, Bertini R, Montopoli M, Cocetta V, Borocci S, Prandi IG, Flavahan K, Bahr M, Napiorkowski A, Chillemi G, Ooka M, Yang XP, Zhang SL, Xia MH, Zheng W, Bonaventura J, Pomper MG, Hooper JE, Morales M, Rosenberg AZ, Nettles KW, Jain SK, Allegretti M, Michaelides M. The SARS-CoV-2 spike protein binds and modulates estrogen receptors<\/strong>. Sci. Adv. 2022;8(48):doi:10.1126\/sciadv.add4150.<\/p>\n Bonaventura J, Gomez JL, Carlton ML, Lam S, Sanchez Soto M, Morris PJ, Moaddel R, Kang HJ, Zanos P, Gould TD, Thomas CJ, Sibley DR, Zarate CA, Michaelides M. Target deconvolution studies of (2R,6R)-hydroxynorketamine: an elusive search<\/strong>. Mol. Psychiatr. 2022;doi:10.1038\/s41380-022-01673-w.<\/p>\n\t\t\t\t\tProjectes seleccionats<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t 21FIS041. Plataforma de Unidades de Investigaci\u00f3n Cl\u00ednica y Ensayos Cl\u00ednicos<\/strong>. Instituto de Salud Carlos III (ISCIII). Budget: 412500. 2021-2023. PI: Hereu Boher, Pilar.<\/p>\n 21DPS003. Subvencions per a la formaci\u00f3 de cient\u00edfics i tecn\u00f2legs: modalitat personal investigador en formaci\u00f3 (PIF-Salut)<\/strong>. Generalitat de Catalunya- Departament de Salut. Budget: 92623,53. 2021-2024. PI: Ciruela Alf\u00e9rez, Francisco.<\/p>\n 21INT002. Ecto-GPR37: a potential biomarker for Parkinson’s disease. MICHAEL J FOX FOUNDATION<\/strong>. Budget: 86218. 2021-2023. PI: Ciruela Alf\u00e9rez, Francisco.<\/p>\n 18CEE003. EUTRAIN: The EUropean TRAnsplantation and INnovation (EU-TRAIN) consortium for improving diagnosis and risk stratification in kidney transplant patients<\/strong>. COMISSI\u00d3 EUROPEA. Budget: 68463,44. 2018-2024. PI: Hereu Boher, Pilar.<\/p>\n 18ACL137. REPETITIVE LEVOSIMENDAN INFUSIONS FOR PATIENTS WITH ADVANCED CHRONIC HEART FAILURE (LEODOR)<\/strong>. Budget: 62592,72. 2018-2023. PI: Hereu Boher, Pilar.<\/p>\n\t\t\t\t\tTransfer\u00e8ncia de tecnologia<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\tPAT084_IP; Concepci\u00f3 Soler i Francisco Ciruela Proyectos financiados por el Instituto de Salud Carlos III (ISCIII) y cofinanciados por el Fondo Europeo de Desarrollo Regional (FEDER):<\/i><\/p>\n <\/p>\n Modulaci\u00f3n molecular de los complejos extrasin\u00e1pticos de receptores NMDA como estrategia terap\u00e9utica para la enfermedad de Alzheimer<\/b><\/p>\n PI13\/00135. 01\/2014-12\/2016. 33.500 \u20ac. IP: Xavier Altafaj.<\/p>\n Desarrollo de herramientas moleculares que permitan desestabilizar los complejos proteicos de los Ex-NMDARs para reducir la neurodegeneraci\u00f3n asociada a la enfermedad de Alzheimer. Dise\u00f1ar y evaluar p\u00e9ptidos de disrupci\u00f3n de las interacciones moleculares de los NMDARs, para reducir la activaci\u00f3n y\/o niveles de los Ex-NMDARs y paliar la neurotoxicidad mediada por los mismos.<\/p>\n <\/p>\n\t\t\t\t\n Neurofarmacologia i Dolor Resum El grup centra la seva recerca en la comprensi\u00f3 de la funci\u00f3 dels receptors de neurotransmissors en salut i malaltia. Per tant, el seu principal objectiu \u00e9s traduir els resultats del laboratori al pacient i la pr\u00e0ctica cl\u00ednica. En conseq\u00fc\u00e8ncia, busquen noves estrat\u00e8gies farmacol\u00f2giques per assolir una gesti\u00f3 efica\u00e7 de malalties […]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":503,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"site-sidebar-layout":"no-sidebar","site-content-layout":"page-builder","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"disabled","ast-breadcrumbs-content":"","ast-featured-img":"disabled","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"publishpress_future_action":{"enabled":false,"date":"2024-05-10 07:58:35","action":"change-status","newStatus":"draft","terms":[],"taxonomy":""},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2091"}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=2091"}],"version-history":[{"count":7,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2091\/revisions"}],"predecessor-version":[{"id":25413,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/2091\/revisions\/25413"}],"up":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/pages\/503"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=2091"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}
\nEP23 382 389.7
\nTREX2 inhibitors\n\t\t\t\t\tM\u00e9s informaci\u00f3<\/a>\n\t\t\t\t\t\t\t\t\t\t\tExpand<\/i><\/a>\n\t\t\t\t\t\n\t\tCiruela Alf\u00e9rez, Francisco\n\t<\/h4>\n
\n\t\t\n\t\tfciruela@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tAso P\u00e9rez, Ester\n\t<\/h4>\n
\n\t\t\n\t\teaso@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tInvestigadors principals\n\t<\/h2>\n\t\t\t\t\n
\n\t\tCiruela Alf\u00e9rez, Francisco\n\t<\/h4>\n
\n\t\t\n\t\tfciruela@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFlores de los Heros, \u00c1frica\n\t<\/h4>\n\t\t\t\t\n
\n\t\tAso P\u00e9rez, Ester\n\t<\/h4>\n
\n\t\t\n\t\teaso@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n\t\t\t\t\n
\n\t\tFern\u00e1ndez Due\u00f1as, V\u00edctor\n\t<\/h4>\n\t\t\t\t\n
\n\t\tBonaventura Morera, Jordi\n\t<\/h4>\n
\n\t\t\n\t\tjbonaventura@idibell.cat\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tENLLA\u00c7OS RELACIONATS\n\t<\/h4>\n
\n\t\t\n\t\tGrup de Neurofarmacologia i Dolor\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\tPlataforma d’Unitats d’Investigaci\u00f3 Cl\u00ednica\n\t\t<\/a>\n\t<\/h4>\n
\n\t\t\n\t\t@UBneuroscience\n\t\t<\/a>\n\t<\/h4>\n
\n\t\tEquip\n\t<\/h2>\n\t\t\t\t\t\t\t\t\t\t\t\tCap de grup\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es principals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es cl\u00ednics\/ques\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es postdoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es predoctorals\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tSuport cient\u00edfic\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tInvestigadors\/es visitants\t\t\t\t<\/a>\n\t\t\t\t\t\t\t\t\t\t\t\tCol\u00b7laboradors\/es\t\t\t\t<\/a>\n\t\t\t\t\t\tCap de grup\n\t\t\t\t\t\t\t\t\t\t\t
\n
\n
\n
\n
\n
\n
\n
\n
\n\t\tNot\u00edcies relacionades\n\t<\/h2>\n\t\t\n\t\t\t\t<\/a>\n\t\t\tDefineixen un mecanisme molecular associat al Parkinson juvenil<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t08\/11\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tEl tractament amb plasma convalescent contra la COVID-19 no \u00e9s efectiu<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t10\/02\/2022\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tTanquem un 2021 ple de ci\u00e8ncia!<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t30\/12\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tF\u00e0rmacs activats amb llum, la medicina localitzada sense efectes secundaris<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t09\/09\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tPossible nou biomarcador de la malaltia de Parkinson<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t25\/03\/2021\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa falta d’interacci\u00f3 entre dos receptors neuronals \u00e9s un factor determinant en l’esquizofr\u00e8nia<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t27\/10\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\t“La recerca \u00e9s la que ens donar\u00e0 el coneixement necessari per poder atacar la pand\u00e8mia” Sebasti\u00e0 Videla<\/a>\n\t\t\tBy comunicacio<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t22\/04\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tExperts en receptors acoblats a prote\u00efna G es reuneixen a la UB per debatre sobre noves perspectives farmacol\u00f2giques<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t17\/02\/2020\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tLa 2a Reuni\u00f3 Europea GRIN2B reuneix a Barcelona experts internacionals i fam\u00edlies afectades per aquesta malaltia minorit\u00e0ria<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t08\/10\/2019\t\t\t\t\t\t\t\n\t\t\n\t\t\t\t<\/a>\n\t\t\tUn tractament amb suplement diet\u00e8tic millora la motricitat i comunicaci\u00f3 d’una pacient amb s\u00edndrome de Rett at\u00edpica<\/a>\n\t\t\tBy Idibell<\/a>\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t | \n\t\t\t\t\t\t\t\t\t18\/06\/2019\t\t\t\t\t\t\t\n\t\t\n\n","protected":false},"excerpt":{"rendered":"